Shots: The approval is based on DUO (NCT02004522) & DYNAMO (NCT01882803) study results assessing Copiktra (25msg bid) vs ofatumumab or rituximab and to either CT or radioimmunotherapy in 319 adults in ratio (1:1) in patients with 2L+ r/r CLL/SLL or 2l+ r/r FL respectively DUO study results: PFS: no of events (55% vs 70%); progression […]Read More
